Pathogenesis and Phenotypes of Pulmonary Vascular Disease in COPD: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative – PH Group 3 Workstream
Pulmonary Circulation · 2026-07 · 16 (3)
DOI: 10.1002/pul2.70409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 10.09.2026. Verfasst von Lucilla Piccari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department Hospital del Mar Pulmonary Hypertension Unit Barcelona Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is frequently associated with pulmonary vascular disease (PVD) yet pulmonary vascular involvement remains underrecognized and incompletely phenotyped. Emerging evidence demonstrates that pulmonary vasculopathy may precede overt emphysema and airflow obstruction, suggesting that vascular remodeling is an early and integral component of COPD pathobiology rather than solely a late consequence of advanced lung disease. Multiple mechanisms contribute to COPD‐associated PVD, including genetic susceptibility, abnormal lung development, cigarette smoke and environmental exposures, endothelial dysfunction, hypoxia, inflammation, hyperinflation, and comorbid cardiovascular and infectious diseases, which are discussed in this paper. These processes lead to heterogeneous clinical phenotypes that span a continuum from early pulmonary vascular abnormalities without resting PH to severe hemodynamically defined PH. Conventional spirometry and resting hemodynamics incompletely capture this complexity, whereas advanced imaging, gas‐exchange assessment, and exercise testing improve identification of pulmonary vascular involvement. Distinct pulmonary vascular phenotypes may carry important implications for exercise limitation, exacerbation risk, progression, and survival. Recognizing COPD‐associated PVD as a continuum rather than a late‐stage complication has major implications for screening, phenotyping, and clinical trial design. This article reflects deliberations of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative (PVRI IDDI) Group 3 Pulmonary Hypertension Workstream on the pathophysiology and phenotypes of PVD in COPD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pulmonology Department Hospital del Mar Pulmonary Hypertension Unit Barcelona Spain.
- University of Maryland - Institute for Health Computing, Bethesda, MD, USA and University of Maryland, School of Medicine, Division of Respiratory Critical Care and Sleep Medicine Baltimore Maryland USA.
- Division of Pulmonary and Critical Care Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA.
- Division of Pulmonolgy, Department of Medicine Stellenbosch University Cape Town South Africa.
- National Pulmonary Hypertension Service, Royal Brompton Hospital, part of Guy's and St Thomas's NHS Trust, London, and National heart and Lung Institute, Imperial College London UK.
- Division of Pulmonary and Critical Care Medicine Brigham and Women's Hospital Boston Massachusetts USA.
ORCID-Profile: Lucilla Piccari, Katarina Zeder, Aparna Balasubramanian, Stephen John Wort, Shelsey W Johnson, Reda E Girgis, Steven H Abman, Sylvia M Nikkho, Steven D Nathan
Zitieren
APA
Piccari, L., Zeder, K., Balasubramanian, A., Allwood, B. W., Wort, S. J., Johnson, S. W., Girgis, R. E., Shlobin, O. A., Abman, S. H., Kovacs, G., Washko, G., Nikkho, S. M., & Nathan, S. D. (2026). Pathogenesis and Phenotypes of Pulmonary Vascular Disease in COPD: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative – PH Group 3 Workstream. Pulmonary Circulation, 16(3). https://doi.org/10.1002/pul2.70409
Vancouver
Piccari L, Zeder K, Balasubramanian A, Allwood BW, Wort SJ, Johnson SW, et al. Pathogenesis and Phenotypes of Pulmonary Vascular Disease in COPD: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative – PH Group 3 Workstream. Pulmonary Circulation. 2026;16(3). doi:10.1002/pul2.70409
BibTeX
@article{Piccari2026,
author = {Piccari, Lucilla and Zeder, Katarina and Balasubramanian, Aparna and Allwood, Brian W and Wort, Stephen John and Johnson, Shelsey W and Girgis, Reda E and Shlobin, Oksana A and Abman, Steven H and Kovacs, Gabor and Washko, George and Nikkho, Sylvia M and Nathan, Steven D},
title = {Pathogenesis and Phenotypes of Pulmonary Vascular Disease in COPD: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative – PH Group 3 Workstream},
journal = {Pulmonary Circulation},
year = {2026},
volume = {16},
number = {3},
doi = {10.1002/pul2.70409}
}
EUVIMED